title: [The characteristics of the action of mildronate (dihydrate 3-(2,2,2-trimethylhydrazine)propionate) on the red blood parameters in heart failure].
abstract: Mildronat potentiates the therapeutic effect of the combined treatment of heart failure, which includes the use of nitro drugs. It also decreases the level of methemoglobin in the patients' blood and improves the phosphate balance, especially that of 2,3-diphosphoglycerate to control oxygen transport by hemoglobin, which is of paramount importance in hypoxia caused by coronary heart disease.
authors.forename: A P
authors.initials: AP
authors.lastname: Sisetskiĭ
authors.forename: V P
authors.initials: VP
authors.lastname: Artiukh
authors.forename: I I
authors.initials: II
authors.lastname: Sakharchuk
authors.forename: N F
authors.initials: NF
authors.lastname: Starodub
mesh_terms: D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000737:chemistry / Q000187:drug effects*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008706:Methemoglobin / Q000032:analysis / Q000187:drug effects; D008763:Methylhydrazines / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D010710:Phosphates / Q000097:blood
chemical_list: D002317:Cardiovascular Agents; D006454:Hemoglobins; D008763:Methylhydrazines; D010710:Phosphates; C050147:3-(2,2,2-trimethylhydrazine)propionate; D008706:Methemoglobin
vernacular_title: Osobennosti deĭstviia mildronata (digidrat 3-(2,2,2-trimetilgidraziniĭ)propionat) na nekotorye parametry krasnoĭ krovi pri serdechnoĭ nedostatochnosti.